NasdaqGS:NVCRMedical Equipment
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)?
Novocure recently reported that its Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) combined with atezolizumab and chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma met its primary endpoint, delivering a statistically significant improvement in disease control versus historical controls.
This outcome adds fresh clinical evidence for TTFields in a highly challenging cancer setting, potentially reinforcing Novocure’s broader effort to expand...